ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO1044

Disparities in CKD Progression Across Racial Groups in Two Large Health Systems

Session Information

Category: CKD (Non-Dialysis)

  • 1901 CKD (Non-Dialysis): Epidemiology, Risk Factors, and Prevention


  • Nicholas, Susanne B., David Geffen School of Medicine at UCLA, Los Angeles, California, United States
  • Daratha, Kenn B., Washington State University, Colbert, Washington, United States
  • Shen, Jenny I., LaBiomed at Harbor-UCLA, Torrance, California, United States
  • Jones, Cami R., Providence St. Joseph Health, Spokane, Washington, United States
  • Duru, Obidiugwu, David Geffen School of Medicine at UCLA, Los Angeles, California, United States
  • McPherson, Sterling, Washington State University College of Medicine, Spokane, Washington, United States
  • Alicic, Radica Z., Providence St. Joseph Health, Spokane, Washington, United States
  • Tuttle, Katherine R., University of Washington School of Medicine, Spokane, Washington, United States
  • Norris, Keith C., David Geffen School of Medicine at UCLA, Los Angeles, California, United States

Group or Team Name


Disparities exist in progression of chronic kidney disease (CKD) across racially diverse groups. The University of California, Los Angeles Health (UCLA) and Providence St. Joseph Health (PSJH) systems formed a CKD and At-risk CKD Data Registry to inform advances in population health, individual behaviors, social and physical environment, and precision medicine.


CKD progression was determined across self-reported racial/ethnic groups in the database (>3.1 million patients) that was populated from electronic health records of adults treated at UCLA and PSJH from 2006 to 2016. Eligibility in the Registry was based on identification of CKD, and at-risk for CKD defined by hypertension, diabetes, or pre-diabetes. Linear regression coefficients for individual trajectories were calculated for patients having at least 3 eGFRs (CKD-EPI-creatinine). Individuals were classified by change in eGFR over time. Linear mixed models were used to assess racial differences in eGFR trajectories, controlling for age, gender, and time-varying measurements of systolic blood pressure, hemoglobin A1C, and renin angiotensin system inhibitor use.


Patients with statistically significant eGFR decline (≥2-3 mL/min/1.73m2/year; n=182,959, 16%) had a baseline of 79±26 mL/min/1.73m2 (mean±SD) versus 81±23 mL/min/1.73m2 in non-decliners (n=980,022, 84%). Non-White were more likely than White patients to experience eGFR decline after adjustment for relevant covariates in multi-variable models. Mortality rate for patients with significant eGFR decline was >3 times higher than in patients without eGFR decline.


In this large data registry from electronic health records at UCLA and PSJH, after multi-variable adjustment Non-White patients with CKD or at-risk for CKD are more likely to experience eGFR decline, which was associated with higher risk of mortality. Future directions include assessing eGFR decline by race/ethnicity and mortality risk in our unique cohort.


  • Private Foundation Support